NT5DC2 and pancreatic adenocarcinoma: Increased expressions of NT5DC2 (RFS HR = 2.62 (1.12-6.13), p = 0.033) and NT5DC4 (RFS: HR = 3.94 (1.16-13.4), p = 0.018) were significantly associated with poorer RFS in patients with PAAD.